Description
NGS: investing in deeper evaluation and optimised therapeutic decisions in myeloid neoplasms
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: NGS: investing in deeper evaluation and optimised therapeutic decisions in myeloid neoplasms
€3.03
Related products
-
1 year access Online Belgian Journal of Hematology (BJH)
€71.94 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in digestive oncology
€3.03 Add to cart
Reviews
There are no reviews yet.